Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress

SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologAds Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute
The 500 largest cellular IoT deployments together account for 632 million units
CNOOC Limited Brings On-stream Suizhong 36-2 Oilfield 36-2 Block Development Project

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Celsius Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CELH
Nvidia plans to set up Taiwan headquarters, local media reports